Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients

被引：0
|
作者：
Streicher, Katie [1 ]
Wang, Jixin [1 ]
Brohawn, Philip Z. [2 ]
Higgs, Brandon W. [2 ]
Tummala, Raj [3 ]
Ranade, Koustubh [1 ]
机构：
[1] MedImmune, Translat Med, Gaithersburg, MD USA
[2] MedImmune LLC, Gaithersburg, MD USA
[3] MedImmune, Gaithersburg, MD USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2684
引用
收藏
页数：2
相关论文
共 50 条
  • [21] TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo
    Puig, Montserrat
    Tosh, Kevin W.
    Schramm, Lynnsie M.
    Grajkowska, Lucja T.
    Kirschman, Kevin D.
    Tami, Cecilia
    Beren, Joel
    Rabin, Ronald L.
    Verthelyi, Daniela
    JOURNAL OF LEUKOCYTE BIOLOGY, 2012, 91 (01) : 147 - 158
  • [22] The imidazoquinoline TLR7 agonist negatively affects virus-induced type I and type III IFN induction pathways in primary human plasmacytoid dendritic cells
    Natalia, Mahwish
    Dai, Jihong
    Singh, Sukhwinder
    Cui, Chongwei
    Fitzgerald-Bocarsly, Patricia
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [23] Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
    Liu, Hao
    Higgs, Brandon
    Rees, William
    Morehouse, Chris
    Streicher, Katie
    Brohawn, P.
    Illei, G.
    Ranade, K.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [24] Cutting Edge: Type I IFN Drives Emergency Myelopoiesis and Peripheral Myeloid Expansion during Chronic TLR7 Signaling
    Buechler, Matthew B.
    Teal, Thomas H.
    Elkon, Keith B.
    Hamerman, Jessica A.
    JOURNAL OF IMMUNOLOGY, 2013, 190 (03): : 886 - 891
  • [25] RETRACTED ARTICLE: Selected TLR7/8 agonist and type I interferon (IFN-α) cooperatively redefine the microglia transcriptome
    Mst Reshma Khatun
    Sarder Arifuzzaman
    Inflammopharmacology, 2023, 31 : 547 - 547
  • [26] TYPE I IFN GENE SIGNATURE TEST-HIGH AND -LOW PATIENTS WITH MODERATE TO SEVERE SLE DISEASE ACTIVITY HAVE DISTINCT GENE EXPRESSION SIGNATURES OF IMMUNOLOGIC PATHWAYS AND CELL TYPES
    Liu, H.
    Higgs, B.
    Rees, W.
    Morehouse, C.
    Streicher, K.
    Brohawn, P.
    Illei, G.
    Ranade, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 180 - 181
  • [27] Type II but Not Type I IFN Signaling Is Indispensable for TLR7-Promoted Development of Autoreactive B Cells and Systemic Autoimmunity
    Chodisetti, Sathi Babu
    Fike, Adam J.
    Domeier, Phillip P.
    Singh, Harinder
    Choi, Nicholas M.
    Corradetti, Chelsea
    Kawasawa, Yuka Imamura
    Cooper, Timothy K.
    Caricchio, Roberto
    Rahman, Ziaur S. M.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (04): : 796 - 809
  • [28] Recognition of Borrelia burgdorferi, the Lyme Disease Spirochete, by TLR7 and TLR9 Induces a Type I IFN Response by Human Immune Cells
    Petzke, Mary M.
    Brooks, Andrew
    Krupna, Michelle A.
    Mordue, Dana
    Schwartz, Ira
    JOURNAL OF IMMUNOLOGY, 2009, 183 (08): : 5279 - 5292
  • [29] Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN (vol 174, pg 4043, pg 2005)
    Bekeredjian-Ding, IB
    Wagner, M
    Hornung, V
    Giese, T
    Schnurr, M
    Endres, S
    Hartmann, G
    JOURNAL OF IMMUNOLOGY, 2005, 174 (09): : 5884 - 5884
  • [30] TLR7 Stimulation of APCs Results in Inhibition of IL-5 through Type I IFN and Notch Signaling Pathways in Human Peripheral Blood Mononuclear Cells
    Edwards, Susan
    Jones, Carolyn
    Leishman, Andrew J.
    Young, Barbara W.
    Matsui, Hiroyuki
    Tomizawa, Hideyuki
    Murray, Clare M.
    Biffen, Mark
    JOURNAL OF IMMUNOLOGY, 2013, 190 (06): : 2585 - 2592
12345